CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control B Mothe, A Llano, J Ibarrondo, J Zamarreño, M Schiaulini, C Miranda, ... PloS one 7 (1), e29717, 2012 | 161 | 2012 |
Mechanisms of abrupt loss of virus control in a cohort of previous HIV controllers M Rosás-Umbert, A Llano, R Bellido, A Olvera, M Ruiz-Riol, M Rocafort, ... Journal of virology 93 (4), 2019 | 45 | 2019 |
Analysis of the cumulative changes in Graves’ disease thyroid glands points to IFN signature, plasmacytoid DCs and alternatively activated macrophages as chronicity determining … M Ruiz-Riol, MPA Barnils, RC Oriol, AS Pla, FEB Serres, A Lucas-Martin, ... Journal of autoimmunity 36 (3-4), 189-200, 2011 | 43 | 2011 |
Expression and function of the IL‐2 receptor in activated human plasmacytoid dendritic cells M Naranjo‐Gómez, H Oliva, N Climent, MA Fernández, M Ruiz‐Riol, ... European journal of immunology 37 (7), 1764-1772, 2007 | 43 | 2007 |
Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial L Bailón, A Llano, S Cedeño, T Escribà, M Rosás-Umbert, M Parera, ... Nature Medicine, 1-11, 2022 | 39 | 2022 |
Methylation regulation of Antiviral host factors, Interferon Stimulated Genes (ISGs) and T-cell responses associated with natural HIV control B Oriol-Tordera, M Berdasco, A Llano, B Mothe, C Gálvez, ... PLoS Pathogens 16 (8), e1008678, 2020 | 36 | 2020 |
In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial M Rosás-Umbert, M Ruiz-Riol, MA Fernández, M Marszalek, P Coll, ... Frontiers in immunology 11, 418, 2020 | 32 | 2020 |
Gut microbiome signatures linked to HIV-1 reservoir size and viremia control A Borgognone, M Noguera-Julian, B Oriol, L Noël-Romas, M Ruiz-Riol, ... Microbiome 10 (1), 1-15, 2022 | 31 | 2022 |
Identification of interleukin-27 (IL-27)/IL-27 receptor subunit alpha as a critical immune axis for in vivo HIV control M Ruiz-Riol, D Berdnik, A Llano, B Mothe, C Gálvez, S Pérez-Álvarez, ... Journal of virology 91 (16), 2017 | 27 | 2017 |
Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected M Ruiz-Riol, A Llano, J Ibarrondo, J Zamarreño, K Yusim, V Bach, ... The Journal of infectious diseases 211 (6), 936-946, 2015 | 25 | 2015 |
Overexpression of metallothionein I/II: a new feature of thyroid follicular cells in Graves' disease M Ruiz-Riol, MJ Martinez-Arconada, N Alonso, B Soldevila, D Marchena, ... The Journal of Clinical Endocrinology & Metabolism 97 (2), 446-454, 2012 | 15 | 2012 |
TLR‐activated conventional DCs promote γ‐secretase‐mediated conditioning of plasmacytoid DCs B Pérez‐Cabezas, M Naranjo‐Gómez, M Ruiz‐Riol, P Bastos‐Amador, ... Journal of leukocyte biology 92 (1), 133-143, 2012 | 14 | 2012 |
Schlafen 12 restricts HIV-1 latency reversal by a codon-usage dependent post-transcriptional block in CD4+ T cells M Kobayashi-Ishihara, KF Smutná, FE Alonso, J Argilaguet, ... bioRxiv, 2022 | 12 | 2022 |
Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture AC Guardo, M Ruiz-Riol, E Fernández, MJ Maleno, ME Bargalló, A Leon, ... Aids 29 (11), 1309-1318, 2015 | 11 | 2015 |
Can we just kick-and-kill HIV: possible challenges posed by the epigenetically controlled interplay between HIV and host immunity M Ruiz-Riol, C Brander Immunotherapy 11 (11), 931-935, 2019 | 10 | 2019 |
Epigenetic landscape in the kick-and-kill therapeutic vaccine BCN02 clinical trial is associated with antiretroviral treatment interruption (ATI) outcome B Oriol-Tordera, A Esteve-Codina, M Berdasco, M Rosás-Umbert, ... EBioMedicine 78, 103956, 2022 | 9 | 2022 |
Benzyl-2-acetamido-2-deoxy-α-d-galactopyranoside increases human immunodeficiency virus replication and viral outgrowth efficacy in vitro A Olvera, JP Martinez, M Casadellà, A Llano, M Rosás, B Mothe, ... Frontiers in immunology 8, 2010, 2018 | 8 | 2018 |
Sirtuin-2, NAD-Dependent Deacetylase, Is a New Potential Therapeutic Target for HIV-1 Infection and HIV-Related Neurological Dysfunction C Duran-Castells, A Llano, A Kawana-Tachikawa, A Prats, ... Journal of Virology 97 (2), e01655-22, 2023 | 5 | 2023 |
Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent J Moltó, M Rosás-Umbert, C Miranda, C Manzardo, MC Puertas, ... Journal of Antimicrobial Chemotherapy 76 (4), 1032-1040, 2021 | 5 | 2021 |
IRF7 expression correlates with HIV latency reversal upon specific blockade of immune activation IJ Ezeonwumelu, E García-Vidal, E Felip, MC Puertas, B Oriol-Tordera, ... Frontiers in immunology, 5026, 2022 | 4 | 2022 |